27% growth in prescriptions dispensed over prior quarter; 147% growth over comparable quarter in 2022. 5 consecutive quarters of double-digit growth. Click here to learn more ›

Efficacy and Safety of the Melanocortin Agonist PL9643 in a Phase 2 Study of Subjects With Dry Eye Disease

Scroll to Top